CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Sweden's Newbury Pharmaceuticals Q4 revenue more than doubles on new product launches 

By Reuters News


Overview

  • Sweden specialty drug maker's Q4 net revenue grew about 130% yr/yr on new launches

  • Q4 EBITDA loss narrowed compared to last year

  • Company secured new generic approvals and exclusive rights to hospital portfolio in Iraq


Outlook

  • Company expects gross margin to improve in coming quarters

  • Company prioritizes reaching EBITDA breakeven as foundation for long-term growth

  • Company remains on track to launch over 30 products in Nordics by Dec 2026


Result Drivers

  • NEW PRODUCT LAUNCHES - Co said Q4 revenue growth was driven by additional product launches and increased participation in tenders across the Nordics

  • MARGIN PRESSURE - Co said gross margin declined due to product mix and price pressure in tenders, limiting earnings improvement despite higher revenue

  • SLOW INTERNATIONAL SALES - Co said international sales were limited as activities in the Middle East progressed slower than expected due to geopolitical factors


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EBITDA

-SEK 5.10 mln


Analyst Coverage

  • The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago


Reuters Recommended Reads

  • Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view

  • Oct 27 - Pharming Group Q3 revenue rises on US demand; tightens guidance

  • Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.